Your browser doesn't support javascript.
loading
Association of ESR1 Germline Variants with TP53 Somatic Variants in Breast Tumors in a Genome-wide Study.
Tjader, Nijole P; Beer, Abigail J; Ramroop, Johnny; Tai, Mei-Chee; Ping, Jie; Gandhi, Tanish; Dauch, Cara; Neuhausen, Susan L; Ziv, Elad; Sotelo, Nereida; Ghanekar, Shreya; Meadows, Owen; Paredes, Monica; Gillespie, Jessica L; Aeilts, Amber M; Hampel, Heather; Zheng, Wei; Jia, Guochong; Hu, Qiang; Wei, Lei; Liu, Song; Ambrosone, Christine B; Palmer, Julie R; Carpten, John D; Yao, Song; Stevens, Patrick; Ho, Weang-Kee; Pan, Jia Wern; Fadda, Paolo; Huo, Dezheng; Teo, Soo-Hwang; McElroy, Joseph Paul; Toland, Amanda E.
Afiliación
  • Tjader NP; Department of Cancer Biology and Genetics, The Ohio State University College of Medicine, Columbus, Ohio.
  • Beer AJ; Department of Cancer Biology and Genetics, The Ohio State University College of Medicine, Columbus, Ohio.
  • Ramroop J; The City College of New York, City University of New York, New York, New York.
  • Tai MC; Cancer Research Malaysia, Subang Jaya, Selangor, Malaysia.
  • Ping J; Division of Epidemiology, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.
  • Gandhi T; Biomedical Sciences, The Ohio State University College of Medicine, Columbus, Ohio.
  • Dauch C; The Ohio State University Medical School, Columbus, Ohio.
  • Neuhausen SL; Department of Cancer Biology and Genetics, The Ohio State University College of Medicine, Columbus, Ohio.
  • Ziv E; The Ohio State University Wexner Medical Center, Clinical Trials Office, Columbus, Ohio.
  • Sotelo N; Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, California.
  • Ghanekar S; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.
  • Meadows O; Department of Medicine, University of California, San Francisco, San Francisco, California.
  • Paredes M; Institute for Human Genetics, University of California San Francisco, San Francisco, California.
  • Gillespie JL; Department of Cancer Biology and Genetics, The Ohio State University College of Medicine, Columbus, Ohio.
  • Aeilts AM; Department of Cancer Biology and Genetics, The Ohio State University College of Medicine, Columbus, Ohio.
  • Hampel H; Biomedical Sciences, The Ohio State University College of Medicine, Columbus, Ohio.
  • Zheng W; Biomedical Sciences, The Ohio State University College of Medicine, Columbus, Ohio.
  • Jia G; The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
  • Hu Q; Department of Internal Medicine, Division of Human Genetics, The Ohio State University, Columbus, Ohio.
  • Wei L; Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California.
  • Liu S; Division of Epidemiology, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.
  • Ambrosone CB; Division of Epidemiology, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.
  • Palmer JR; Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
  • Carpten JD; Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
  • Yao S; Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
  • Stevens P; Department of Cancer Control and Prevention, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
  • Ho WK; Slone Epidemiology Center at Boston University, Boston, Massachusetts.
  • Pan JW; City of Hope Comprehensive Cancer Center, Duarte, California.
  • Fadda P; Department of Integrative Translational Sciences, City of Hope, Duarte, California.
  • Huo D; Department of Cancer Control and Prevention, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
  • Teo SH; Bioinformatics Shared Resource, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
  • McElroy JP; Cancer Research Malaysia, Subang Jaya, Selangor, Malaysia.
  • Toland AE; School of Mathematical Sciences, Faculty of Science and Engineering, University of Nottingham Malaysia, Semenyih, Selangor, Malaysia.
Cancer Res Commun ; 4(6): 1597-1608, 2024 Jun 27.
Article en En | MEDLINE | ID: mdl-38836758
ABSTRACT
In breast tumors, somatic mutation frequencies in TP53 and PIK3CA vary by tumor subtype and ancestry. Emerging data suggest tumor mutation status is associated with germline variants and genetic ancestry. We aimed to identify germline variants that are associated with somatic TP53 or PIK3CA mutation status in breast tumors. A genome-wide association study was conducted in 2,850 women of European ancestry with breast cancer using TP53 and PIK3CA mutation status (positive or negative) as well as specific functional categories [e.g., TP53 gain-of-function (GOF) and loss-of-function, PIK3CA activating] as phenotypes. Germline variants showing evidence of association were selected for validation analyses and tested in multiple independent datasets. Discovery association analyses found five variants associated with TP53 mutation status with P values <1 × 10-6 and 33 variants with P values <1 × 10-5. Forty-four variants were associated with PIK3CA mutation status with P values <1 × 10-5. In validation analyses, only variants at the ESR1 locus were associated with TP53 mutation status after multiple comparisons corrections. Combined analyses in European and Malaysian populations found ESR1 locus variants rs9383938 and rs9479090 associated with the presence of TP53 mutations overall (P values 2 × 10-11 and 4.6 × 10-10, respectively). rs9383938 also showed association with TP53 GOF mutations (P value 6.1 × 10-7). rs9479090 showed suggestive evidence (P value 0.02) for association with TP53 mutation status in African ancestry populations. No other variants were significantly associated with TP53 or PIK3CA mutation status. Larger studies are needed to confirm these findings and determine if additional variants contribute to ancestry-specific differences in mutation frequency.

SIGNIFICANCE:

Emerging data show ancestry-specific differences in TP53 and PIK3CA mutation frequency in breast tumors suggesting that germline variants may influence somatic mutational processes. This study identified variants near ESR1 associated with TP53 mutation status and identified additional loci with suggestive association which may provide biological insight into observed differences.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Proteína p53 Supresora de Tumor / Mutación de Línea Germinal / Receptor alfa de Estrógeno / Estudio de Asociación del Genoma Completo / Fosfatidilinositol 3-Quinasa Clase I Límite: Adult / Female / Humans / Middle aged Idioma: En Revista: Cancer Res Commun Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Proteína p53 Supresora de Tumor / Mutación de Línea Germinal / Receptor alfa de Estrógeno / Estudio de Asociación del Genoma Completo / Fosfatidilinositol 3-Quinasa Clase I Límite: Adult / Female / Humans / Middle aged Idioma: En Revista: Cancer Res Commun Año: 2024 Tipo del documento: Article